Vaxcyte, Inc. DEF 14A Filing

TL;DR

<b>Vaxcyte, Inc. has filed its DEF 14A proxy statement detailing executive compensation and corporate governance for the fiscal year ending December 31, 2023.</b>

AI Summary

Vaxcyte, Inc. (PCVX) filed a Proxy Statement (DEF 14A) with the SEC on April 15, 2024. Vaxcyte, Inc. filed a DEF 14A form on April 15, 2024. The filing pertains to the fiscal year ending December 31, 2023. The company's principal executive offices are located at 825 Industrial Road, Ste. 300, San Carlos, CA 94070. Vaxcyte, Inc. was formerly known as SutroVax, Inc., with a name change on July 24, 2015. The filing includes data related to stock awards and option awards for covered fiscal years.

Why It Matters

For investors and stakeholders tracking Vaxcyte, Inc., this filing contains several important signals. This DEF 14A filing provides crucial information for shareholders regarding executive compensation, director elections, and other matters to be voted on at the annual meeting. Shareholders can use this document to understand how executive compensation is structured and how it aligns with company performance, aiding informed voting decisions.

Risk Assessment

Risk Level: — Vaxcyte, Inc. shows moderate risk based on this filing. The filing is a routine DEF 14A, which is standard for public companies and does not contain new material financial or operational information that would significantly alter risk assessment.

Analyst Insight

Shareholders should review the executive compensation details and any proposed governance changes to make informed voting decisions at the upcoming annual meeting.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-04-15 — Filing Date (Date of filing)
• 2015-07-24 — Date of Name Change (From SutroVax, Inc. to Vaxcyte, Inc.)

Key Players & Entities

• Vaxcyte, Inc. (company) — Filer name
• SutroVax, Inc. (company) — Former company name
• 2024-04-15 (date) — Filing date
• 2024-06-06 (date) — Period of report
• 2023-12-31 (date) — Fiscal year end
• 825 Industrial Road, Ste. 300, San Carlos, CA 94070 (address) — Business address

FAQ

Industry Context

Vaxcyte, Inc. operates in the biotechnology sector, focusing on the development of vaccines. This DEF 14A filing is typical for publicly traded companies in this industry.

Regulatory Implications

As a publicly traded company, Vaxcyte, Inc. is subject to SEC regulations, including the requirement to file DEF 14A statements for shareholder votes and disclosures.

What Investors Should Do

1. Review Vaxcyte's executive compensation structure and performance metrics.
2. Examine director nominations and qualifications presented in the filing.
3. Understand proposals requiring shareholder vote and cast accordingly.

Key Dates

• 2024-04-15: Filing Date — DEF 14A filed by Vaxcyte, Inc.
• 2024-06-06: Period of Report — The period covered by the filing.
• 2023-12-31: Fiscal Year End — The fiscal year to which the filing pertains.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure for public companies and does not represent a change in reporting frequency or type compared to previous filings of the same nature.

Filing Documents

• d21304ddef14a.htm (DEF 14A) — 774KB
• g21304g01g01.jpg (GRAPHIC) — 267KB
• g21304g02g02.jpg (GRAPHIC) — 240KB
• g21304g02m02.jpg (GRAPHIC) — 31KB
• g21304g31l03.jpg (GRAPHIC) — 103KB
• g21304g76i41.jpg (GRAPHIC) — 102KB
• 0001193125-24-096192.txt (&nbsp;) — 3303KB
• pcvx-20231231.xsd (EX-101.SCH) — 5KB
• pcvx-20231231_def.xml (EX-101.DEF) — 5KB
• pcvx-20231231_lab.xml (EX-101.LAB) — 7KB
• pcvx-20231231_pre.xml (EX-101.PRE) — 4KB
• d21304ddef14a_htm.xml (XML) — 215KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 27

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 55 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 58 HOUSEHOLDING OF PROXY MATERIALS 59 OTHER MATTERS 59 Special Note Regarding Forward-Looking Statements This proxy statement contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "seek," "should," "target," "will," or "would," or the negative of these words or other similar terms or expressions. Actual events or results may differ from those expressed in forward-looking statements. You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this proxy statement primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission and other subsequent documents we file with the Securities and Exchange Commission. The Company expressly disclaims any obligation to update or alter any statements as a result of new information, future events or otherwise, except as required by law. Table of

View Full Filing

View this DEF 14A filing on SEC EDGAR